Drug intelligence / Profile preview

BI-113608

Development stage: Phase 1
Lead developer: Boehringer
Modality: Small Molecules
Administration: Oral

Overview

BI-113608 is an investigational small molecule drug initially developed by Boehringer Ingelheim. It has been studied primarily for the treatment of chronic obstructive pulmonary disease (COPD) in patients with symptoms of chronic bronchitis. The drug has also been evaluated in clinical trials to assess its pharmacokinetics and potential interactions with other medications, such as ketoconazole and voriconazole. As of the latest available information, its highest global R&D status is pending, and it remains under development for respiratory indications.

Targets

DGAT2 (Hepatic diacylglycerol acyltransferase 2)

Beyond the preview

Go deeper on BI-113608.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI-113608.

Explore the full profile